Nuvation Bio (NUVB) has had the lowest return since January 1, 2026 by a mid-cap US stock, returning -28%.
| ASSET | % RETURN |
|---|---|
Nuvation Bio (NUVB) | -27.98% |
Abercrombie & Fitch (ANF) | -18.36% |
Wave Life Sciences (WVE) | -18.27% |
Alphatec (ATEC) | -16.24% |
Terns Pharmaceuticals (TERN) | -15.63% |
Super (SGHC) | -14.29% |
Sportradar (SRAD) | -14.25% |
Abivax SA American Depositary Shares (ABVX) | -13.74% |
Bellring Brands LLC (BRBR) | -13.29% |
Gulfport Energy Operating (GPOR) | -12.87% |
Travere Therapeutics (TVTX) | -12.81% |
ODDITY Tech Ltd Class A Ordinary Shares (ODD) | -12.56% |
Klaviyo (KVYO) | -12.55% |
Melco Resorts & Entertainment (MLCO) | -12.16% |
360 DigiTech (QFIN) | -12.08% |
Braze (BRZE) | -12.03% |
CVR Energy (CVI) | -12.02% |
Wix (WIX) | -11.93% |
Ocular Therapeutix (OCUL) | -11.51% |
Centessa Pharmaceuticals PLC ADR (CNTA) | -11.5% |
eToro (ETOR) | -11.32% |
Teleflex (TFX) | -11.31% |
Soleno Therapeutics (SLNO) | -11.26% |
Dyne Therapeutics (DYN) | -10.87% |
Viking Therapeutics (VKTX) | -10.64% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
